What tesamorelin studies found
Tesamorelin lowered deep belly fat during HIV care
Trials followed fat inside the belly and liver. They also tracked IGF-1, a liver-made protein showing the hormone message arrived.
Tesamorelin asks a gland to release growth hormone
Tesamorelin copies a message the brain normally sends. The message reaches a gland sitting under the brain. That gland releases the body's own growth hormone [4]. The shot isn't bottled growth hormone.
Scientists changed the medicine so blood can't break it apart too soon [3]. The change gives the message time to reach the gland. You don't need the chemistry to understand the result. The shot lasts long enough to do its job.
U.S. officials approved tesamorelin in 2010 [5]. The approval covers a belly-fat problem linked with HIV care. At a clinic, visits and blood tests help doctors watch your response.
Tesamorelin trials found less fat in two places
The final large test before approval is called a Phase 3 trial. One such trial followed 412 volunteers on HIV treatment. They got 2 milligrams per day.
Scans found that fat near their organs had shrunk. Doctors saw triglycerides, a blood fat, fall 50 milligrams per deciliter, or per tenth of a liter. Without the starting level, that figure can't show the size of the change by itself. The liver-made protein IGF-1 also rose [1].
With longer care, belly fat stayed about 18% below its starting level [2]. One study measured 37% less liver fat [7]. The comparison used placebo, a shot holding no medicine. Another scan study found the same liver change [6].
Researchers combined five trials in a 2026 review [8]. The combined results again showed a drop near the organs. The tesamorelin and visceral fat page shows those scans, while the tesamorelin and liver fat page covers liver scans. You can compare the two sets of findings.
Tesamorelin approval covers one group
U.S. officials approved tesamorelin in 2010 for one group [5]. The group has HIV and too much fat tucked around the organs. People without HIV aren't included. Ordinary weight loss isn't included either.
The main trials enrolled people taking HIV medicine [1][2]. Large fat-loss trials haven't tested healthy adults. Sports groups also ban tesamorelin during contests.
Is tesamorelin FDA approved gives the exact boundary. Safety signals reported in the trials lists the risks doctors watched. You can take that list to your doctor.
Tesamorelin carries a message from the brain
Tesamorelin acts like a message already made in your brain [3][4]. The message arrives at the hormone gland beneath it. Growth hormone comes out in reply. Scientists changed the medicine so blood won't destroy the message too early.
Trial volunteers received one morning shot under belly skin [1]. The shot wasn't growth hormone itself. It raised IGF-1, a liver-made growth protein. Doctors used that blood reading to confirm the gland had answered.
Tesamorelin does not supply bottled growth hormone
Tesamorelin prompted brief releases of the body's own growth hormone [1][4]. It didn't add bottled hormone to the blood. Those releases raised IGF-1, a liver-made protein involved in using stored fat.
Approval covers one belly-fat problem tied to HIV care [5]. A use outside that group is called off-label, meaning the drug agency hasn't approved it. Tesamorelin mechanism of action is the medical name for the steps behind the shot. You can use that meaning when another claim appears.
Later studies answered two narrower questions
These notes come from medical journals, not sales pages, and each paper names the people and result. A 2026 review drew together five trials. It again found less belly fat [8]. A 2024 study found belly and liver fat fell among people taking newer HIV medicines [9].
A 2025 study asked whether tesamorelin improved memory and focus. It found no gain in either one [10]. The 2007 and 2008 trials remain the main belly-fat tests [1][2]. You can use those dates to tell early proof from later questions.